School of Medicine
Showing 141-160 of 164 Results
-
Allyson Spence
Clinical Assistant Professor, Medicine - Oncology
BioAllyson Spence MD, PhD is a Clinical Assistant Professor of Medicine in the Stanford University School of Medicine. She received her MD, PhD in the MSTP program at Vanderbilt University School of Medicine, studying basic mechanisms of transcription using Saccharomyces cerevisiae as a model system in the laboratory of Dr. Tony Weil. She went on to an internship and residency at the University of Pennsylvania before returning to Stanford to complete her Oncology fellowship training. She did a postdoctoral fellowship at Stanford in the department of Molecular Biology under the auspices of Dr. Margaret Fuller, where she was the recipient of a career award.
She has transitioned from basic science research to clinical medicine where she sees patients diagnosed with breast cancer. Additionally, she has an appointment at the Palo Alto VA as a staff oncologist where she focuses on women's cancers and women at high risk of developing breast and gynecologic cancers. She is involved in several translational research projects at the VA, as well as being involved in clinical trials. -
Sandy Srinivas
Professor of Medicine (Oncology) and, by courtesy, of Urology
Current Research and Scholarly InterestsClinical interests: general oncology, genito-urinary malignancy Research interests: conducting clinical trials in advanced prostate cancer, bladder cancer and renal cell carcinoma
-
Frank E. Stockdale
Maureen Lyles D'Ambrogio Professor in the School of Medicine, Emeritus
Current Research and Scholarly InterestsLaboratory and clinical research in breast cancer ; Normal and abornal differentiation and growth
-
Takeshi Sugio
Instructor, Medicine - Oncology
BioI am a physician-scientist and hematologist focused on clinical translation of T-cell biology. I received my MD from Kyushu University, and subsequently completed Residency Training at Toranomon Hospital, the largest transplant center in Japan. I continued my Hematology training at Kyushu University, where I qualified as a Board-certified specialist (2017) and supervisory hematologist (2021) by the Japanese Society of Hematology. For my PhD (2014-19), I studied expression profiles and histologic features of TCLs. I discovered distinct TCL clinical groups identified by infiltrating immune cell patterns in the microenvironment. Based on my dissertation work (Sugio, et al 2018 Blood Advances), I planned and conducted a Phase II trial of PD1 inhibition for relapsed/refractory TCL (UMIN000034499). I joined the Alizadeh lab at Stanford in 2021, where I am developing tools to analyze immune status using liquid biopsies.
-
Fangdi Sun
Assistant Professor of Medicine (Oncology)
BioDr. Sun is a medical oncologist and clinical investigator at Stanford University. She specializes in the treatment of patients with head and neck malignancies, with specific interests in virus-driven malignancies and novel, biomarker-guided therapies in head and neck cancer. She received her medical degree from Harvard Medical School, followed by a residency and chief residency at the University of California, San Francisco, and then served as chief fellow in hematology and medical oncology at Stanford University. She has earned honors and recognition from the American Association of Cancer Research (AACR), American Society of Clinical Oncology (ASCO), and International Association for the Study of Lung Cancer (IASLC), among other organizations.
-
Melinda L. Telli, M.D.
Professor of Medicine (Oncology)
Current Research and Scholarly InterestsMy research focuses on the development of novel therapies for the treatment of triple-negative and hereditary cancer. Other areas of interest include prevention of cardiac damage associated with breast cancer treatment and cardiotoxicity of anti-cancer agents.
-
Stefano Testa, MD
Instructor, Medicine - Oncology
BioDr. Stefano Testa is a board-certified, fellowship-trained medical oncologist with Stanford Health Care. He is also a clinical instructor in the Department of Medicine, Division of Oncology at Stanford University School of Medicine.
Dr. Testa specializes in treating patients with sarcomas and other solid tumors using cellular therapy approaches. He has expertise in adoptive T-cell therapies, including chimeric antigen receptor T-cell (CAR-T) and T-cell receptor (TCR) therapies.
As a physician-scientist, Dr. Testa focuses on developing next-generation cellular therapies for solid tumors, particularly sarcomas. His research goal is to identify targets for adoptive T-cell therapies in solid tumors, including soft tissue and bone sarcomas, and on novel synthetic biology approaches to enhance the effectiveness of T-cell therapies against solid tumors.
Dr. Testa has authored numerous peer-reviewed publications in leading medical journals, including Immunity, Cancer Discovery, JAMA Network Open, Genome Medicine, and Biomacromolecules. He has presented his research at national and international scientific meetings, including the Connective Tissue Oncology Society Annual Meeting and the Society for Immunotherapy of Cancer Annual Meeting.
Dr. Testa is a member of the American Society of Clinical Oncology (ASCO), Connective Tissue Oncology Society (CTOS), the American Society of Hematology (ASH), and the Society for Immunotherapy of Cancer (SITC). -
Haluk Tezcan, MD
Adjunct Clinical Associate Professor, Medicine - Oncology
BioClinical focus:
Breast Oncology
Molecular Diagnostics
Dr. Tezcan is a medical oncologist and hematologist with over three decades of diverse experience in cancer management and research.
He is leading the clinical development of Droplet Biosciences' novel liquid biopsy technology, a first-in-class lymphatic fluid molecular residual disease assessment, overseeing the scientific and clinical development of the technology. With over three decades of direct patient care and clinical trial experience as a principal investigator and director, both in academia and private practice, he has a firsthand understanding of the unmet clinical needs of physicians and patients, as well as broad experience in clinical trial design and implementation.
He is also co-principal at Athea Oncology, guiding practices and hospitals in developing clinical trial programs and high-value real-world data collection and diagnostic companies in clinical development. He is also a reviewer of JCO Precision Medicine.
Before joining Athea Oncology and Droplet Biosciences, he was the co-founder of LexentBio, which was successfully acquired by Roche/FMI. He also served as Director of Translational Medicine at Genomic Health and as Vice President, leading oncology development at Counsyl, where he integrated science with clinical product development. He established the CA.RE.foundation, a cancer research foundation dedicated to enabling the execution of clinical trials across community oncology sites throughout the Northwest US. He has independently built multiple software tools to help oncologists navigate the practical realities of their daily work. -
Heather Wakelee
Winston Chen and Phyllis Huang Professor
Current Research and Scholarly InterestsDr. Wakelee's research is focused on clinical trials and translational efforts in patients with lung cancer and other thoracic malignancies such as thymoma and thymic carcinoma. Other interests include translation projects in thoracic malignancies and collaborations with population scientists regarding lung cancer questions.
